Physicians Ponder CD20 Bispecifics’ Transition To Community As Lunsumio US Debut Approaches

With multiple anti-CD20xCD3 bispecific antibodies hitting the market for B-cell non-Hodgkin lymphomas (NHL), it remains as yet unclear how to differentiate them in the clinic in terms of efficacy and safety, although they will likely play a complementary role to chimeric antigen receptor T-cell (CAR-T) cell therapies.

But the bigger question is how to move them from the hospital and cancer center setting where patients have typically received them and into the community oncology setting where physicians may still struggle